Chemotherapy Induced Nausea and Vomiting and Quality of Life of Patients On Moderate And Highly Emetogenic Chemotherapy
Chemotherapy Induced Nausea and Vomiting and Quality of Life of Patients On Moderate And Highly Emetogenic Chemotherapy
复制标题
中度和高度致吐化疗患者化疗引起的恶心呕吐及生活质量
DOI：
10.1093/annonc/mdz343.046
复制
发表时间：
2019
影响因子：
50.5
通讯作者：
W. Z. W. Ishak
中科院分区：
文献类型：
--
作者：
Eznal Izwadi Bin Mohd Mahidin;W. Z. W. Ishak
背景化疗引起的恶心和呕吐（CINV）是癌症治疗中患者最害怕的症状。该研究的目的是分析CINV与中度（MEC）或高度致吐性化疗（HEC）方案相关对患者生活质量（QOL）的影响。方法对马来亚大学医学中心接受MEC或HEC的患者进行前瞻性观察研究，88例患者符合纳入标准。根据国家指南给患者开标准止吐药。从化疗前一天到第5天，每个患者填写一个周期的日记，其中包括呕吐史的细节。患者在化疗前（基线）和每个周期后第5天完成自我报告欧洲研究与癌症组织（EORTC）核心生活质量问卷（QLQ-C30），连续3个周期。为了评估CINV对生活质量的影响，我们计算了QLQ-C30每个域的基线和第5天HQL评估评分的变化，并比较了3个亚组患者：1)恶心和呕吐，2)恶心但没有呕吐，3)既不恶心也不呕吐。结果第1周期呕吐33例（37.5%），第2周期呕吐34例（38.6%），第3周期呕吐38例（43.2%）。恶心方面，50例（56.8%）出现恶心周期1,58例（65.9%）出现恶心周期2和3。结论：该研究表明，尽管使用标准的止吐剂治疗，但MEC或HEC患者没有发生CINV。我们证明没有CINV的患者有更好的生活质量。
Abstract Background Chemotherapy-induced nausea and vomiting (CINV) in cancer treatment are symptoms most feared by patients (pts). The study aim is to analyze the impact of CINV associated to moderately (MEC) or highly emetogenic chemotherapy (HEC) regimes on pts’ quality of life (QOL). Methods Prospective observational study was done among pts receiving MEC or HEC in University Malaya Medical Center. 88 patients (pts) fulfilled the inclusion criteria. Pts were prescribed standard antiemesis based on national guidelines. Each pt filled up a diary for each cycle from the day before chemotherapy up to day 5 days which included details of emesis history. Pts completed the self-report European Organization for Research and Cancer (EORTC) core Quality of Life Questionnaire (QLQ-C30) before chemotherapy (baseline) and day 5 after each cycles, for 3 consecutive cycles. To estimate the effects of CINV on QOL, the change in scores between the baseline and day 5 HQL assessments was calculated for each domain the QLQ-C30 and compared in 3 subgroups of pts: 1) with both nausea and vomiting, 2) with nausea but no vomiting, 3) with neither nausea nor vomiting. Results Total of 33 pts (37.5%) develop vomiting during cycle 1, 34 (38.6%) in cycle 2 and 38 (43.2%) in cycle 3. For nausea, 50 pts (56.8%) developed nausea cycle 1, 58 patients (65.9%) in cycle 2 and 3. The incidence of vomiting is higher in female (p-value Conclusion The study demonstrated a significant no of pts who underwent MEC or HEC suffered CINV despite the use of standard anti-emetics treatment. We demonstrated that pts who did not suffer from CINV have better QOL.